Soumitra S Ghosh

USPTO Granted Patents = 58 (Patent Applications = 18)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 25)

Average Co-Inventor Count = 4.4

ph-index = 16

Forward Citations = 1,102(Granted Patents)

Forward Citations (Not Self Cited) = 1,088(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Wilmington, DE (US) (2015)
San Diego, CA (US) (1988 - 2023)

Company Filing History:

21 out of 164

Amylin Pharmaceuticals, Inc.

patents

15 out of 38

Astrazeneca Pharmaceuticals LP

Siska Diagnostics, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of California

patents

9. 1 out of 2,198

Smithkline Beecham Corporation

patents

10. 1 out of 4

Aegerion Pharmaceuticals, Inc.

patents

11. 1 out of 1,153

Vanderbilt University

patents

12. 1 out of 3

Amryt Pharmaceuticals Inc.

14. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2023

Loading Chart...

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11827690 - ApoC-II mimetic peptides (2023-11-28),

2. 11535659 - Engineered polypeptides having enhanced duration of action (2022-12-27),

3. 11357829 - Systems, compositions and methods for treating diabetes (2022-06-14),

4. 11136372 - ApoC-II mimetic peptides (2021-10-05),

5. 9879063 - Engineered polypeptides having enhanced duration of action and reduced immunogenicity (2018-01-30),

6. 9593154 - Engineered polypeptides having enhanced duration of action (2017-03-14),

7. 9453063 - Hybrid polypeptides with selectable properties (2016-09-27),

8. 9382304 - Engineered polypeptides having enhanced duration of action with reduced immunogenicity (2016-07-05),

9. 9249181 - C-terminal amidation of polypeptides (2016-02-02),

10. 9217022 - GLP-1 receptor agonist compounds having stabilized regions (2015-12-22),

11. 9133260 - GIP analog and hybrid polypeptides with selectable properties (2015-09-15),

12. 8906849 - Pancreatic polypeptide family motifs, polypeptides and methods comprising the same (2014-12-09),

13. 8895498 - GIP and exendin hybrid polypeptides (2014-11-25),

14. 8759295 - Peptide-peptidase inhibitor conjugates and methods of using same (2014-06-24),

15. 8697647 - Hybrid polypeptides with selectable properties (2014-04-15),

Of course, I'd be glad to assist with that! Here is the article about inventor Soumitra S Ghosh:

Title: The Innovative Mind of Soumitra S Ghosh

Introduction: Soumitra S Ghosh, a talented inventor based in San Diego, CA (US), has made significant contributions to the field of medical science through his numerous patented inventions.

Latest Patents: Among his impressive portfolio of 58 patents, two of his recent inventions stand out. The first patent relates to ApoC-II mimetic peptides, offering a novel approach to treating hypertriglyceridemia. The second patent focuses on engineered polypeptides with enhanced duration of action, showcasing his commitment to developing innovative pharmaceutical solutions for various diseases and disorders.

Career Highlights: Soumitra S Ghosh has honed his expertise while working with reputable companies such as Amylin Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. His groundbreaking research and inventions have paved the way for novel treatment options in areas like dyslipidemia, Alzheimer's disease, and metabolic disorders.

Collaborations: Throughout his career, Soumitra S Ghosh has collaborated with esteemed peers such as Odile Esther Levy and Robert E Davis. Together, they have fostered a culture of innovation and excellence, leading to the development of cutting-edge medical solutions.

Conclusion: Soumitra S Ghosh's relentless pursuit of innovation and his commitment to improving healthcare make him a standout figure in the world of inventors. His remarkable patents and collaborative efforts underscore his dedication to advancing medical science and improving patient outcomes.

If you need further information or assistance, feel free to ask!

This text is generated by artificial intelligence and may not be accurate.